FDA Clears IND for Phase 2 VT-7208 Study in Chronic Spontaneous Urticaria
The U.S. FDA cleared an investigational new drug application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria.
Related stories
Beijing Urban Construction Design Public Float Falls Below 25% Minimum
The company’s public float was 23.70% as of Oct. 30, below the required 25% minimum.
L impact | REGULATION | Oct 30, 2026, 04:03 AM UTC
USFDA Approves Sun Pharma’s Supplemental Biologics License Application for Ilumya
M impact | REGULATION | Oct 30, 2026, 02:37 AM UTC
Indonesia Exempts Coal for Off-Grid Plants From Domestic Market Obligation
M impact | REGULATION | Oct 30, 2026, 02:13 AM UTC
Prosecutors Appeal Oh Se-hoon’s Second-Trial Acquittal
A special counsel appealed Oh Se-hoon’s acquittal in a second trial on political-fund law charges.
L impact | REGULATION | Oct 30, 2026, 01:51 AM UTC
France to Deploy Officers for Halloween Protests
The French government announced the deployment amid the risk of violence during Halloween protests.
M impact | REGULATION | Oct 30, 2026, 01:34 AM UTC
Netanyahu Wins Israeli Election, but His Bloc Falls Short of a Majority
The final count shows Netanyahu won the election, but his bloc did not secure a majority.
M impact | REGULATION | Oct 30, 2026, 01:34 AM UTC